☰
×
Top 20
Insights
Insight+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Novartis
Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at...
June 28, 2022
Novartis Publishes Results from Two and Three-Copy Cohorts of Zolgensma in P-III (SPR1NT) Trial for Spinal Muscular Atrophy in the...
June 20, 2022
Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gli...
June 8, 2022
Novartis’ Kymriah (tisagenlecleucel) CAR-T Cell Therapy Receives the US FDA’s Approval for the Treatment of Follicular Lymphoma
May 30, 2022
Insights+: The US FDA New Drug Approvals in April 2022
May 19, 2022
Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advan...
May 5, 2022
Load more...
No more records!